NCT04791839 is a Phase 2 clinical trial of Zimberelimab in Non Small Cell Lung Cancer, sponsored by Washington University School of Medicine.

Who is sponsoring NCT04791839?

NCT04791839 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT04791839?

Interventions in NCT04791839: Zimberelimab, Domvanalimab, Etrumadenant.

What condition does NCT04791839 study?

NCT04791839 studies Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer.

Is NCT04791839 still recruiting?

NCT04791839 is currently active, enrolled. Last updated 5 November 2025.

Last reviewed 2025-11-05 · How we verify

NCT04791839

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Active, enrolled Phase 2 Last updated 5 November 2025

What this trial tests

Phase 2 trial testing Zimberelimab in Non Small Cell Lung Cancer in 30 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

4 August 2021

Primary endpoint
30 April 2026

30 June 2030

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	4 August 2021
Primary completion	30 April 2026
Estimated completion	30 June 2030
Sites	1 location across United States

Drugs / interventions tested

Zimberelimab — full drug profile →
Domvanalimab — full drug profile →
Etrumadenant — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Non-small Cell Carcinoma — all drugs for Non-small Cell Carcinoma →
Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer or Non-small Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Since anti-PD1, anti-TIGIT, and A2R antagonists have complementary mechanisms of action, and the latter two have shown synergism in combination with antibodies against PD-1, othis study aims to evaluate the efficacy and tolerability of the triplet combination of zimberelimab, domvanalimab, and etrumadenant in patients with non-small cell lung cancer previously treated with immune checkpoint blockade therapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, et al · · 2022 · cited 253× · PMID 35222404 · DOI 10.3389/fimmu.2022.823618
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C, Dellepiane C, Carrega P, Sommariva S, et al · · 2021 · cited 168× · PMID 35069581 · DOI 10.3389/fimmu.2021.799455
Exploiting innate immunity for cancer immunotherapy.
Yi M, Li T, Niu M, Mei Q, et al · · 2023 · cited 151× · PMID 38008741 · DOI 10.1186/s12943-023-01885-w
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.
Chu X, Tian W, Wang Z, Zhang J, et al · · 2023 · cited 147× · PMID 37291608 · DOI 10.1186/s12943-023-01800-3
Adenosine and Inflammation: Here, There and Everywhere.
Pasquini S, Contri C, Borea PA, Vincenzi F, et al · · 2021 · cited 122× · PMID 34299305 · DOI 10.3390/ijms22147685
Anti-TIGIT therapies for solid tumors: a systematic review.
Rousseau A, Parisi C, Barlesi F. · · 2023 · cited 111× · PMID 36933320 · DOI 10.1016/j.esmoop.2023.101184
Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
Zhang P, Liu X, Gu Z, Jiang Z, et al · · 2024 · cited 69× · PMID 38229100 · DOI 10.1186/s40364-023-00543-z
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X, Xie L. · · 2022 · cited 54× · PMID 35836249 · DOI 10.1186/s13046-022-02430-1

Verify or expand the search:

Other trials of Zimberelimab

Trials testing the same drug.

NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
NCT07283848 — Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma · Phase 2 · withdrawn
NCT06431633 — Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously · Phase 3 · recruiting
NCT06759649 — A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies · Phase 1 · recruiting
NCT06155396 — A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard T · Phase 2 · recruiting

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04791839 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 5 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04791839.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing